fda crackdown on compounded semaglutide How FDA Crackdowns Are Affecting GLP-1 Use In 2025

The FDA is proposing the removal of three GLP-1 drugs from the 503B bulks list of active ingredients that outsourcing facilities can use to make compounded medicines, the agency announced on Thursday

21.10

★★★★☆4.8 (126)

🚨 FDA Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like semaglutide and tirzepatide, signaling a major shift in how these

21.28

★★★★★4.9 (98)

The FDA is cracking down on ‘misleading’ compounded GLP-1s from telehealth companies., Compounded weight loss drugs are not FDA-approved, which means the agency does not review their safety,

21.12

★★★★★5.0 (157)

FDA Intensifies Crackdown on GLP-1 Compounding

28.57

★★★★★4.7 (84)

The FDA has removed semaglutide injection products (GLP-1) from the shortage list, ending the temporary rule that allowed pharmacies to compound these medications, often used for weight loss. Compounded drugs are custom-made

22.95

★★★★★4.9 (203)

GLP-1 Compounding Crackdown

29.96

★★★★★5.0 (176)

Are off-brand versions of popular weight loss drugs safe?

25.22

★★★★★4.8 (132)